Answer
Abecma is indicated for adults with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose disease progressed on the last therapy.
Sources for this answer
- Abecma 260 - 500 x 10^6 cells dispersion for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.1 Therapeutic Indications · Version 3Document updated
Sources checked